Jane Street’s Standard BioTools LAB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-769,231
| Closed | -$985K | – | 12344 |
|
|
2025
Q4 | $985K | Buy |
769,231
+376,212
| +96% | +$505K | ﹤0.01% | 6153 |
|
|
2025
Q3 | $511K | Buy |
393,019
+357,423
| +1,004% | +$468K | ﹤0.01% | 7813 |
|
|
2025
Q2 | $42.7K | Buy |
+35,596
| New | +$39.5K | ﹤0.01% | 9213 |
|
|
2025
Q1 | – | Sell |
-236,833
| Closed | -$414K | – | 10086 |
|
|
2024
Q4 | $414K | Buy |
236,833
+55,019
| +30% | +$102K | ﹤0.01% | 7163 |
|
|
2024
Q3 | $351K | Sell |
181,814
-60,340
| -25% | -$118K | ﹤0.01% | 7775 |
|
|
2024
Q2 | $429K | Sell |
242,154
-1,141,543
| -82% | -$2.79M | ﹤0.01% | 7266 |
|
|
2024
Q1 | $3.75M | Buy |
1,383,697
+1,067,748
| +338% | +$2.58M | ﹤0.01% | 3051 |
|
|
2023
Q4 | $698K | Buy |
315,949
+280,316
| +787% | +$598K | ﹤0.01% | 6200 |
|
|
2023
Q3 | $103K | Sell |
35,633
-2,883
| -7% | -$7.54K | ﹤0.01% | 7941 |
|
|
2023
Q2 | $74.3K | Sell |
38,516
-223,418
| -85% | -$441K | ﹤0.01% | 8108 |
|
|
2023
Q1 | $511K | Buy |
261,934
+188,224
| +255% | +$372K | ﹤0.01% | 6275 |
|
|
2022
Q4 | $86.2K | Buy |
73,710
+48,462
| +192% | +$59.7K | ﹤0.01% | 8178 |
|
|
2022
Q3 | $28K | Sell |
25,248
-158,337
| -86% | -$239K | ﹤0.01% | 9103 |
|
|
2022
Q2 | $294K | Buy |
183,585
+164,182
| +846% | +$406K | ﹤0.01% | 7640 |
|
|
2022
Q1 | $70K | Sell |
19,403
-20,644
| -52% | -$71.3K | ﹤0.01% | 9585 |
|
|
2021
Q4 | $157K | Sell |
40,047
-6,891
| -15% | -$32.3K | ﹤0.01% | 8974 |
|
|
2021
Q3 | $309K | Sell |
46,938
-42,757
| -48% | -$281K | ﹤0.01% | 8122 |
|
|
2021
Q2 | $553K | Buy |
89,695
+32,372
| +56% | +$173K | ﹤0.01% | 7044 |
|
|
2021
Q1 | $259K | Sell |
57,323
-129,812
| -69% | -$713K | ﹤0.01% | 7905 |
|
|
2020
Q4 | $1.12M | Buy |
187,135
+173,586
| +1,281% | +$1.14M | ﹤0.01% | 4457 |
|
|
2020
Q3 | $101K | Buy |
+13,549
| New | +$93.5K | ﹤0.01% | 6750 |
|
|
2019
Q4 | – | Sell |
-13,793
| Closed | -$64K | – | 5454 |
|
|
2019
Q3 | $64K | Buy |
+13,793
| New | +$109K | ﹤0.01% | 4845 |
|
|
2018
Q4 | – | Sell |
-17,280
| Closed | -$129K | – | 5363 |
|
|
2018
Q3 | $129K | Buy |
17,280
+4,808
| +39% | +$34.2K | ﹤0.01% | 4805 |
|
|
2018
Q2 | $74K | Buy |
+12,472
| New | +$71.1K | ﹤0.01% | 4780 |
|
|
2015
Q4 | – | Sell |
-11,453
| Closed | -$93K | – | 4250 |
|
|
2015
Q3 | $93K | Buy |
+11,453
| New | +$180K | ﹤0.01% | 3376 |
|
|
2014
Q2 | – | Sell |
-5,657
| Closed | -$249K | – | 2876 |
|
|
2014
Q1 | $249K | Buy |
+5,657
| New | +$249K | ﹤0.01% | 2153 |
|
Other funds holding LAB
CC
MCO
LFCM
VCM
HBWM
Jane Street's LAB Position: Q1 2026 in Review
Jane Street sold out of Standard BioTools (LAB) in Q1 2026, closing a stake of 769,231 shares — an estimated $985K sold.
Jane Street first reported a position in LAB in Q1 2014 and held it in 26 quarters. The position peaked at $3.75M in Q1 2024. 155 funds tracked by Wall St. Rank hold LAB as of Q1 2026.
- Jane Street reported no remaining Standard BioTools position as of Q1 2026 after selling out during the quarter.
- Jane Street sold 769,231 Standard BioTools shares in Q1 2026, an estimated $985K.
- Jane Street first reported a position in Standard BioTools in Q1 2014 and held it in 26 quarters.
- Jane Street's Standard BioTools position peaked at $3.75M in Q1 2024.
- 155 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2026.
Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.